A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease

Antioxidation and adjustable treatment strategies are critical for the effective treatment of Alzheimer's disease (AD). Here, we design a dual-targeted Prussian blue nanoformulation (PTCN) that can cross the blood-brain barrier and target amyloid beta aggregates further exert antioxidant effect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dongju Zhao, Yuqing Tang, Xinjun Suo, Chaonan Zhang, Yan Dou, Jin Chang
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Alzheimer's disease dual-targeted nanoformulation adjustable dosing strategy antioxidation prevention and therapy Science (General) Q1-390
Acceso en línea:	https://doaj.org/article/075fcd76bbe94a41bff1b9118de1097e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:075fcd76bbe94a41bff1b9118de1097e
record_format	dspace
spelling	oai:doaj.org-article:075fcd76bbe94a41bff1b9118de1097e2021-11-28T04:38:59ZA dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease2666-675810.1016/j.xinn.2021.100160https://doaj.org/article/075fcd76bbe94a41bff1b9118de1097e2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666675821000850https://doaj.org/toc/2666-6758Antioxidation and adjustable treatment strategies are critical for the effective treatment of Alzheimer's disease (AD). Here, we design a dual-targeted Prussian blue nanoformulation (PTCN) that can cross the blood-brain barrier and target amyloid beta aggregates further exert antioxidant effects. An adjustable gradient dosing strategy with PTCN is used for the first time to design the preventive and therapeutic trials based on the severity of oxidative stress at different AD stages. The results show that PTCN could effectively ameliorate AD-related pathological processes, improve the cognitive decline, and rescue hippocampal atrophy of APP/PS1 mice in both preventive and therapeutic trials. Altogether, PTCN provided here is a successful combination of three traditional biomaterials with good biosafety, which has broad prospects for the early prevention, mild remission, and late treatment of AD, and is expected to be developed into personalized therapeutic drugs and healthcare products for clinical AD in the future. Public summary: • Dual-targeted PTCN that were assembled from traditional biomaterials can traverse the blood-brain barrier, target Aβ aggregates, exert antioxidant effects and ameliorate other pathological processes • The adjustable PTCN dosing strategy designed according to the OS level of AD stages can improve cognitive decline and hippocampal atrophy of APP/PS1 mice in both preventive and therapeutic trials • PTCN has broad prospects for the early prevention, mild remission and late treatment of ADDongju ZhaoYuqing TangXinjun SuoChaonan ZhangYan DouJin ChangElsevierarticleAlzheimer's diseasedual-targeted nanoformulationadjustable dosing strategyantioxidationprevention and therapyScience (General)Q1-390ENThe Innovation, Vol 2, Iss 4, Pp 100160- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer's disease dual-targeted nanoformulation adjustable dosing strategy antioxidation prevention and therapy Science (General) Q1-390
spellingShingle	Alzheimer's disease dual-targeted nanoformulation adjustable dosing strategy antioxidation prevention and therapy Science (General) Q1-390 Dongju Zhao Yuqing Tang Xinjun Suo Chaonan Zhang Yan Dou Jin Chang A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
description	Antioxidation and adjustable treatment strategies are critical for the effective treatment of Alzheimer's disease (AD). Here, we design a dual-targeted Prussian blue nanoformulation (PTCN) that can cross the blood-brain barrier and target amyloid beta aggregates further exert antioxidant effects. An adjustable gradient dosing strategy with PTCN is used for the first time to design the preventive and therapeutic trials based on the severity of oxidative stress at different AD stages. The results show that PTCN could effectively ameliorate AD-related pathological processes, improve the cognitive decline, and rescue hippocampal atrophy of APP/PS1 mice in both preventive and therapeutic trials. Altogether, PTCN provided here is a successful combination of three traditional biomaterials with good biosafety, which has broad prospects for the early prevention, mild remission, and late treatment of AD, and is expected to be developed into personalized therapeutic drugs and healthcare products for clinical AD in the future. Public summary: • Dual-targeted PTCN that were assembled from traditional biomaterials can traverse the blood-brain barrier, target Aβ aggregates, exert antioxidant effects and ameliorate other pathological processes • The adjustable PTCN dosing strategy designed according to the OS level of AD stages can improve cognitive decline and hippocampal atrophy of APP/PS1 mice in both preventive and therapeutic trials • PTCN has broad prospects for the early prevention, mild remission and late treatment of AD
format	article
author	Dongju Zhao Yuqing Tang Xinjun Suo Chaonan Zhang Yan Dou Jin Chang
author_facet	Dongju Zhao Yuqing Tang Xinjun Suo Chaonan Zhang Yan Dou Jin Chang
author_sort	Dongju Zhao
title	A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
title_short	A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
title_full	A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
title_fullStr	A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
title_full_unstemmed	A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease
title_sort	dual-targeted multifunctional nanoformulation for potential prevention and therapy of alzheimer's disease
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/075fcd76bbe94a41bff1b9118de1097e
work_keys_str_mv	AT dongjuzhao adualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT yuqingtang adualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT xinjunsuo adualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT chaonanzhang adualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT yandou adualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT jinchang adualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT dongjuzhao dualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT yuqingtang dualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT xinjunsuo dualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT chaonanzhang dualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT yandou dualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease AT jinchang dualtargetedmultifunctionalnanoformulationforpotentialpreventionandtherapyofalzheimersdisease
_version_	1718408238263697408

A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease

Ejemplares similares